Daré Bioscience Announces Results of 2024 Annual Meeting, Stockholders Approve Reverse Split Authorization

Dare Bioscience, Inc.

Re-elected directors Jessica D. Grossman, M.D. (28,626,331 for) and Susan L. Kelley, M.D. (28,623,481 for) as Class I directors.
Ratified Haskell & White LLP as independent auditor for FY2024 with 53,420,221 votes for, 1,624,718 against.
Advisory approval of named executive officer compensation received 26,182,433 votes for, 3,556,256 against, 594,264 abstentions.
Approved reverse stock split authorization at ratio between 1-for-2 and 1-for-12, with 42,657,404 for, 10,792,335 against.
Approved meeting adjournment proposal to solicit additional proxies if needed, with 44,780,743 votes for.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.